+

WO1998050065A3 - Utilisation de principes actifs a effet biologique pour influer sur l'espace extracellulaire de cellules sensorielles et procede de commande d'administration de principe actif et dispositif approprie - Google Patents

Utilisation de principes actifs a effet biologique pour influer sur l'espace extracellulaire de cellules sensorielles et procede de commande d'administration de principe actif et dispositif approprie Download PDF

Info

Publication number
WO1998050065A3
WO1998050065A3 PCT/EP1998/001951 EP9801951W WO9850065A3 WO 1998050065 A3 WO1998050065 A3 WO 1998050065A3 EP 9801951 W EP9801951 W EP 9801951W WO 9850065 A3 WO9850065 A3 WO 9850065A3
Authority
WO
WIPO (PCT)
Prior art keywords
active substances
influencing
administration
controlling
device used
Prior art date
Application number
PCT/EP1998/001951
Other languages
German (de)
English (en)
Other versions
WO1998050065A2 (fr
Inventor
Marion Sangster Eckmiller
Original Assignee
Marion Sangster Eckmiller
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Marion Sangster Eckmiller filed Critical Marion Sangster Eckmiller
Priority to CA002288631A priority Critical patent/CA2288631A1/fr
Priority to EP98924097A priority patent/EP0980256A2/fr
Priority to AU76417/98A priority patent/AU7641798A/en
Publication of WO1998050065A2 publication Critical patent/WO1998050065A2/fr
Publication of WO1998050065A3 publication Critical patent/WO1998050065A3/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

L'invention concerne l'utilisation d'un principe actif influant sur l'homéostasie du calcium de cellules pour traiter les dégénérescences de cellules sensorielles et de cellules adjacentes.
PCT/EP1998/001951 1997-05-05 1998-04-02 Utilisation de principes actifs a effet biologique pour influer sur l'espace extracellulaire de cellules sensorielles et procede de commande d'administration de principe actif et dispositif approprie WO1998050065A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CA002288631A CA2288631A1 (fr) 1997-05-05 1998-04-02 Utilisation de principes actifs a effet biologique pour influer sur l'espace extracellulaire de cellules sensorielles et procede de commande d'administration de principe actif et dispositif approprie
EP98924097A EP0980256A2 (fr) 1997-05-05 1998-04-02 Utilisation de principes actifs a effet biologique pour influer sur l'espace extracellulaire de cellules sensorielles et procede de commande d'administration de principe actif et dispositif approprie
AU76417/98A AU7641798A (en) 1997-05-05 1998-04-02 The use of biologically active substances for influencing the extracellular areaof sensory cells and method for controlling the administration of active substa nces and device used therein

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE1997118826 DE19718826A1 (de) 1997-05-05 1997-05-05 Verwendung biologisch aktiver Wirkstoffe zum Beeinflussen des Extrazellulär-Raumes von Sinneszellen und Verfahren zur Wirkstoff-Administrationssteuerung
DE19718826.5 1997-05-05

Publications (2)

Publication Number Publication Date
WO1998050065A2 WO1998050065A2 (fr) 1998-11-12
WO1998050065A3 true WO1998050065A3 (fr) 1999-06-10

Family

ID=7828596

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1998/001951 WO1998050065A2 (fr) 1997-05-05 1998-04-02 Utilisation de principes actifs a effet biologique pour influer sur l'espace extracellulaire de cellules sensorielles et procede de commande d'administration de principe actif et dispositif approprie

Country Status (5)

Country Link
EP (1) EP0980256A2 (fr)
AU (1) AU7641798A (fr)
CA (1) CA2288631A1 (fr)
DE (1) DE19718826A1 (fr)
WO (1) WO1998050065A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ID27083A (id) 1998-03-05 2001-02-22 Senju Pharma Co Komposisi farmasi untuk pencegahan dan pengobatan penyakit-penyakit yang behubungan dengan sitopati jaringan okuler fundus
FR2784030B1 (fr) * 1998-10-02 2002-12-20 Inst Nat Sante Rech Med Utilisation de bloqueurs des canaux calciques et/ou cgmp-dependants pour le traitement de pathologies de la retine
US6864243B1 (en) * 2000-05-12 2005-03-08 Inspire Pharmaceuticals, Inc. Method for treating retinal degeneration with purinergic receptor agonists
JP4758641B2 (ja) * 2003-12-12 2011-08-31 千寿製薬株式会社 α−ケトアミド誘導体、その製造方法、及びその用途
KR101055236B1 (ko) 2003-12-12 2011-08-08 센주 세이야꾸 가부시키가이샤 알파-케토아미드 유도체, 및 이의 제조 방법 및 용도
DE102009056597A1 (de) * 2009-12-02 2011-06-09 Tobias Brockmann Verwendung von Flavin-Derivaten zur Behandlung von Pathologien an der Membrana limitans interna (ILM)
JP7100019B2 (ja) 2016-08-19 2022-07-12 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ 選択的エストロゲン受容体モジュレーター（ｓｅｒｍ）は、光受容体の変性に対する保護を付与する
WO2020036658A2 (fr) * 2018-04-27 2020-02-20 The Johns Hopkins University Médicaments favorisant la survie des photorécepteurs du bâtonnet rétinien

Citations (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3995057A (en) * 1974-04-19 1976-11-30 Wilhelm Horrmann Ophthalmological method
US4188394A (en) * 1978-05-08 1980-02-12 Nelson Research & Development Company Ophthalmic composition and method of use
JPS5718609A (en) * 1980-07-08 1982-01-30 Senjiyu Seiyaku Kk Intraocular hypotensor
JPS5732229A (en) * 1980-08-05 1982-02-20 Eiji Sakata Preventing agent against kinesia
JPS57130923A (en) * 1981-02-07 1982-08-13 Eiji Sakata Remedy and preventive for vertigo
SU1297862A1 (ru) * 1980-07-03 1987-03-23 Институт цитологии и генетики СО АН СССР Средства дл лечени пигментной дегенерации сетчатки
WO1990006118A1 (fr) * 1988-12-05 1990-06-14 Houston Biotechnology Incorporated Utilisation therapeutique de dihydropyrimidones et de derives de benzazepine et de benzothiazepine dans le disfonctionnement du nerf optique ou retinien
WO1990012590A1 (fr) * 1989-04-14 1990-11-01 State Of Oregon, State Board Of Higher Education, Oregon Health Sciences University Traitement de maladies oculaires par modulation de metaloproteinases matricielles et leur inhibiteur
EP0430539A2 (fr) * 1989-11-22 1991-06-05 Visionex, Inc. Insert ophtalmique
US5098443A (en) * 1989-03-23 1992-03-24 University Of Miami Method of implanting intraocular and intraorbital implantable devices for the controlled release of pharmacological agents
EP0485232A1 (fr) * 1990-11-08 1992-05-13 Unitika Ltd. Inhibiteurs de néovascularisation
WO1992007580A1 (fr) * 1990-11-05 1992-05-14 Biosource Genetics Corporation Utilisations therapeutiques de la melanine
JPH04182432A (ja) * 1990-11-19 1992-06-30 Toshio Tanaka カルシウム依存性環状ヌクレオチドホスホジエステラーゼ阻害剤
US5156852A (en) * 1989-04-20 1992-10-20 La Haye Laboratories, Inc. Composition and method for combating macular degeneration
WO1993015608A1 (fr) * 1992-02-14 1993-08-19 Regeneron Pharmaceuticals, Inc. Facteurs specifiques prevenant les lesions et la degenerescence retinales
CN1077092A (zh) * 1992-04-10 1993-10-13 张勇 一种眼保健饮料的制备方法
CN1082896A (zh) * 1992-07-18 1994-03-02 苏州第六制药厂 止晕栓制备方法
JPH06234645A (ja) * 1993-02-09 1994-08-23 Toagosei Chem Ind Co Ltd 血管新生阻害剤
WO1994025020A1 (fr) * 1993-04-28 1994-11-10 Pharmacia Ab Procede et moyen d'inhibition de l'opacification de la capsule posterieure
US5421818A (en) * 1993-10-18 1995-06-06 Inner Ear Medical Delivery Systems, Inc. Multi-functional inner ear treatment and diagnostic system
WO1995015958A1 (fr) * 1993-12-08 1995-06-15 Alcon Laboratories, Inc. Composes presentant une puissante activite d'antagonistes du calcium et d'antioxydants et leur utilisation en tant qu'agents cytoprotecteurs
JPH07215892A (ja) * 1994-01-27 1995-08-15 Sumitomo Pharmaceut Co Ltd 突発性難聴治療用医薬組成物
CN1108539A (zh) * 1994-03-16 1995-09-20 吴生武 治疗近视眼药水
WO1995034302A2 (fr) * 1994-06-16 1995-12-21 Allergan Procede utile pour reduire la pression intraoculaire dans l'×il mammalien a l'aide de composes chelatant le calcium
WO1996030366A1 (fr) * 1995-03-28 1996-10-03 Ferrer Internacional, S.A. Polymorphes a et b de 1-(diphenylmethyl)-4-[3-(2-phenyle-1,3-dioxolan-2-yle)propyle]piperazine
WO1996036334A1 (fr) * 1995-05-19 1996-11-21 University Of East Anglia Utilisation des inactivateurs du stockage intracellulaire du calcium comme inhibiteurs de la croissance cellulaire
WO1996041638A1 (fr) * 1995-06-13 1996-12-27 Sanofi Winthrop, Inc. Inhibiteurs de la calpaine destines au traitement de maladies neurodegeneratives
WO1996041805A1 (fr) * 1993-12-08 1996-12-27 Alcon Laboratories, Inc. Dihydropyridines ayant une puissante activite d'antagoniste du calcium et antioxydante et leur utilisation comme agents cytoprotecteurs
CA2188817A1 (fr) * 1995-10-25 1997-04-26 Chiho Fukiage Inhibiteur de l'angiogenese
WO1997029756A1 (fr) * 1996-02-21 1997-08-21 Inspire Pharmaceuticals, Inc. Procede de traitement de l'otite moyenne avec des uridines-triphosphates et des composes apparentes
WO1997034586A2 (fr) * 1996-03-22 1997-09-25 Cytotherapeutics, Inc. Dispositif et methode de traitement de maladies ophtalmiques
WO1998001128A1 (fr) * 1996-07-05 1998-01-15 Mendes S.R.L. Utilisation de l-acetylcarnitine, de l-isovalerycarnitine, de l-propionylcarnitine pour augmenter les taux de igf-1
WO1998018485A1 (fr) * 1996-10-31 1998-05-07 Alcon Laboratories, Inc. Utilisation d'inhibiteurs de calpaine pour traiter des affections neuronales oculaires
EP0848952A1 (fr) * 1996-12-03 1998-06-24 Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. Utilisation des alkanoyles l-carnitines basses pour le traitement des rétinopathies

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH658595A5 (de) * 1983-08-17 1986-11-28 Inst Khim Fiz An Sssr Retinoprotektor zur behandlung von augenerkrankungen.
WO1993010798A1 (fr) * 1991-12-04 1993-06-10 Uab Research Foundation Anticorps monoclonal dirige contre la molecule d'adhesion des cellules gliales et procede d'utilisation
US5252568A (en) * 1992-01-24 1993-10-12 Texas A&M University System Treatment of low pressure glaucoma and ischemic retinal degeneration with loxapine
US5266580A (en) * 1992-01-24 1993-11-30 Texas A&M University System Treatment of low pressure glaucoma and ischemic retinal degeneration with droperidol

Patent Citations (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3995057A (en) * 1974-04-19 1976-11-30 Wilhelm Horrmann Ophthalmological method
US4188394A (en) * 1978-05-08 1980-02-12 Nelson Research & Development Company Ophthalmic composition and method of use
SU1297862A1 (ru) * 1980-07-03 1987-03-23 Институт цитологии и генетики СО АН СССР Средства дл лечени пигментной дегенерации сетчатки
JPS5718609A (en) * 1980-07-08 1982-01-30 Senjiyu Seiyaku Kk Intraocular hypotensor
JPS5732229A (en) * 1980-08-05 1982-02-20 Eiji Sakata Preventing agent against kinesia
JPS57130923A (en) * 1981-02-07 1982-08-13 Eiji Sakata Remedy and preventive for vertigo
WO1990006118A1 (fr) * 1988-12-05 1990-06-14 Houston Biotechnology Incorporated Utilisation therapeutique de dihydropyrimidones et de derives de benzazepine et de benzothiazepine dans le disfonctionnement du nerf optique ou retinien
WO1990006123A1 (fr) * 1988-12-05 1990-06-14 Houston Biotechnology Incorporated Utilisation therapeutique d'agents bloquant l'entree de calcium dans le dysfonctionnement du nerf retinie ou optique
US5098443A (en) * 1989-03-23 1992-03-24 University Of Miami Method of implanting intraocular and intraorbital implantable devices for the controlled release of pharmacological agents
WO1990012590A1 (fr) * 1989-04-14 1990-11-01 State Of Oregon, State Board Of Higher Education, Oregon Health Sciences University Traitement de maladies oculaires par modulation de metaloproteinases matricielles et leur inhibiteur
US5156852A (en) * 1989-04-20 1992-10-20 La Haye Laboratories, Inc. Composition and method for combating macular degeneration
EP0430539A2 (fr) * 1989-11-22 1991-06-05 Visionex, Inc. Insert ophtalmique
WO1992007580A1 (fr) * 1990-11-05 1992-05-14 Biosource Genetics Corporation Utilisations therapeutiques de la melanine
EP0485232A1 (fr) * 1990-11-08 1992-05-13 Unitika Ltd. Inhibiteurs de néovascularisation
JPH04182432A (ja) * 1990-11-19 1992-06-30 Toshio Tanaka カルシウム依存性環状ヌクレオチドホスホジエステラーゼ阻害剤
WO1993015608A1 (fr) * 1992-02-14 1993-08-19 Regeneron Pharmaceuticals, Inc. Facteurs specifiques prevenant les lesions et la degenerescence retinales
CN1077092A (zh) * 1992-04-10 1993-10-13 张勇 一种眼保健饮料的制备方法
CN1082896A (zh) * 1992-07-18 1994-03-02 苏州第六制药厂 止晕栓制备方法
JPH06234645A (ja) * 1993-02-09 1994-08-23 Toagosei Chem Ind Co Ltd 血管新生阻害剤
WO1994025020A1 (fr) * 1993-04-28 1994-11-10 Pharmacia Ab Procede et moyen d'inhibition de l'opacification de la capsule posterieure
US5421818A (en) * 1993-10-18 1995-06-06 Inner Ear Medical Delivery Systems, Inc. Multi-functional inner ear treatment and diagnostic system
WO1996041805A1 (fr) * 1993-12-08 1996-12-27 Alcon Laboratories, Inc. Dihydropyridines ayant une puissante activite d'antagoniste du calcium et antioxydante et leur utilisation comme agents cytoprotecteurs
WO1995015958A1 (fr) * 1993-12-08 1995-06-15 Alcon Laboratories, Inc. Composes presentant une puissante activite d'antagonistes du calcium et d'antioxydants et leur utilisation en tant qu'agents cytoprotecteurs
JPH07215892A (ja) * 1994-01-27 1995-08-15 Sumitomo Pharmaceut Co Ltd 突発性難聴治療用医薬組成物
CN1108539A (zh) * 1994-03-16 1995-09-20 吴生武 治疗近视眼药水
WO1995034302A2 (fr) * 1994-06-16 1995-12-21 Allergan Procede utile pour reduire la pression intraoculaire dans l'×il mammalien a l'aide de composes chelatant le calcium
WO1996030366A1 (fr) * 1995-03-28 1996-10-03 Ferrer Internacional, S.A. Polymorphes a et b de 1-(diphenylmethyl)-4-[3-(2-phenyle-1,3-dioxolan-2-yle)propyle]piperazine
WO1996036334A1 (fr) * 1995-05-19 1996-11-21 University Of East Anglia Utilisation des inactivateurs du stockage intracellulaire du calcium comme inhibiteurs de la croissance cellulaire
WO1996041638A1 (fr) * 1995-06-13 1996-12-27 Sanofi Winthrop, Inc. Inhibiteurs de la calpaine destines au traitement de maladies neurodegeneratives
CA2188817A1 (fr) * 1995-10-25 1997-04-26 Chiho Fukiage Inhibiteur de l'angiogenese
EP0771565A2 (fr) * 1995-10-25 1997-05-07 Senju Pharmaceutical Co., Ltd. Inhibiteur d'angiogenèse
WO1997029756A1 (fr) * 1996-02-21 1997-08-21 Inspire Pharmaceuticals, Inc. Procede de traitement de l'otite moyenne avec des uridines-triphosphates et des composes apparentes
WO1997034586A2 (fr) * 1996-03-22 1997-09-25 Cytotherapeutics, Inc. Dispositif et methode de traitement de maladies ophtalmiques
WO1998001128A1 (fr) * 1996-07-05 1998-01-15 Mendes S.R.L. Utilisation de l-acetylcarnitine, de l-isovalerycarnitine, de l-propionylcarnitine pour augmenter les taux de igf-1
WO1998018485A1 (fr) * 1996-10-31 1998-05-07 Alcon Laboratories, Inc. Utilisation d'inhibiteurs de calpaine pour traiter des affections neuronales oculaires
EP0848952A1 (fr) * 1996-12-03 1998-06-24 Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. Utilisation des alkanoyles l-carnitines basses pour le traitement des rétinopathies

Non-Patent Citations (20)

* Cited by examiner, † Cited by third party
Title
BENNETT J. ET AL: "Photoreceptor Cell Rescue in Retinal Degeneration (rd) Mice by In Vivo Gene Therapy", NATURE MEDICINE, vol. 2, no. 6, 1996, pages 649 - 654, XP002088221 *
DATABASE EPODOC EPO; 13 October 1993 (1993-10-13), YONG ZHANG: "Preparation of beverage caring for eyes", XP002076671 *
DATABASE EPODOC EPO; 2 March 1994 (1994-03-02), ZHAOQING ZHU: "Process for preparing dizzy-stopping suppository", XP002076672 *
DATABASE EPODOC EPO; 20 September 1995 (1995-09-20), SHENGWU WU: "Eyedrops for curing myopia", XP002076670 *
DATABASE WPI Section Ch Week 8210, Derwent World Patents Index; Class A96, AN 82-18654E, XP002088226 *
DATABASE WPI Section Ch Week 8238, Derwent World Patents Index; Class B05, AN 82-80006E, XP002088224 *
DATABASE WPI Section Ch Week 8741, Derwent World Patents Index; Class B02, AN 87-290829, XP002076673 *
DATABASE WPI Section Ch Week 9232, Derwent World Patents Index; Class B06, AN 92-265116, XP002088225 *
DATABASE WPI Section Ch Week 9438, Derwent World Patents Index; Class B02, AN 94-307573, XP002088223 *
DATABASE WPI Section Ch Week 9542, Derwent World Patents Index; Class B04, AN 95-323471, XP002088222 *
LI J. ET AL: "Amelioration of Retinal Photic Injury by a combination of Flunarizine and Dimethylurea", EXPERIMENTAL EYE RESEARCH, vol. 56, no. 1, 1993, pages 71 - 78, XP002088220 *
MEDLINE, AN 72009827 *
MIZUKOSHI K. ET AL: "Clinical Evaluation of Medical Treatment for Meniere's Disease, using a Double-Blind Controlled Study", AMERICAN JOURNAL OF OTOLOGY, vol. 9, no. 5, 1988, pages 418 - 422, XP000654235 *
PATENT ABSTRACTS OF JAPAN vol. 006, no. 102 (C - 107) 11 June 1982 (1982-06-11) *
POTAPOV I.I. ET AL: "Therapy of Meniere's disease and otogenic vestibular disorders by means of intravenous injection of sodium hydrogencarbonate", VESTNIK OTORINOLARINGOLOGII, vol. 33, no. 3, 1971, pages 40 - 44 *
PROSDOCIMO G ET AL: "EFFETTO DELLA L-ACETILCARNITINA SULLA SOGLIA DI SENSIBILITA MACULARE IN PAZIENTI AFFETTI DA DEGENERATZIONE MACULARE SENILE NON ESSUDATIVA. NOTA PRELIMINARE", BOLLETTINO DI OCULISTICA, vol. 67, no. 4, 1988, pages 609 - 612, XP002058278 *
PROSDOCIMO G ET AL: "MIGLIORAMENTO DELLE PRESTAZIONI FUNZIONALI DELL'OCCHIO SENILE DOPO TERAPIA CON L-ACETILCARNITINA", BOLLETTINO DI OCULISTICA, vol. 70, no. 1, 1991, pages 57 - 61, XP002058277 *
RASCOL O. ET AL: "Antivertigo Medications and Drug-Induced Vertigo", DRUGS, vol. 50, no. 5, 1995, pages 777 - 791, XP002088219 *
VAN BOCKXMEER F.M. ET AL: "Taxol for the Treatment of Proliferative Vitreoretinopathy", INVESTIGATIVE OPHTHALMOLOGY AND VISUAL SCIENCE, vol. 26, no. 8, 1985, pages 1140 - 1147, XP002088218 *
WRIGHT J. V. ET AL: "Improvement of vision in macular degeneration associated with intravenous zinc and selenium therapy: two cases", J. NUTR. MED., vol. 1, no. 2, 1990, pages 133 - 138, XP002076668 *

Also Published As

Publication number Publication date
EP0980256A2 (fr) 2000-02-23
DE19718826A1 (de) 1998-11-12
CA2288631A1 (fr) 1998-11-12
WO1998050065A2 (fr) 1998-11-12
AU7641798A (en) 1998-11-27

Similar Documents

Publication Publication Date Title
DE69830095D1 (de) Pharmazeutischer, kosmetischer oder dermo-pharmazeutischer Patch zur Verabreichung mehrerer verschiedenartiger Aktivstoffe
AU1610495A (en) Monitoring water treatment agent in-system concentration and regulating dosage
DE69841076D1 (de) System implantierbarer geräte zur beobachtung und beeinflussung von körperparametern
BR9710362A (pt) Composto formula-ao farmaceutica utiliza-ao de um composto processos de tratamento de um ser humano ou animal sofrendo de uma mediada por atividade anormal de cinase de proteina tirosina e para a prepara-ao de um composto
WO1999032135A8 (fr) Formulations du facteur-2 de croissance des keratinocytes
AU3866097A (en) Naphtholactams and lactones as bone morphogenetic protein active agents
EE200000065A (et) Bioloogiliselt aktiivseid makromolekule ja vett sisaldavad aerosoolpreparaadid ja nende aerosoolide saamise meetod
AU9040098A (en) Compounds and method for the prevention and treatment of diabetic retinopathy
PL321898A1 (en) Application of inorganic aerogles in pharmaceutics
ZA9811799B (en) Solid galenic form of the controlled release tablet type for the instant and then prolonged release of one or more active substances
HUP9902867A3 (en) Therapeutic use of vegf protein or nucleic acid coding same and implant, especially for the treatment of intimal hyperplasia
AU3689595A (en) Device for use in the laser treatment of biological tissue (variants thereof)
DK0948340T3 (da) Biologisk aktive stoffer, fremgangsmåde til deres fremstilling og forbindelser med indhold deraf
ATE249819T1 (de) Präparate zur äusserlichen anwendung zur behandlung von dermatosen
WO1997003188A3 (fr) Utilisation de mp52 ou de mp121 pour la therapie et la prophylaxie de maladies du systeme nerveux
NO992408D0 (no) FremgangsmÕte for lavavfalls fremstilling av skiveformige formlegemer inneholdende aktive ingredienser, og transdermale terapeutiske systemer inneholdende samme
WO1998050065A3 (fr) Utilisation de principes actifs a effet biologique pour influer sur l'espace extracellulaire de cellules sensorielles et procede de commande d'administration de principe actif et dispositif approprie
IT1290781B1 (it) Agente attivo terapeutico per il trattamento di malattie degenerative neuronali.
DE69825319D1 (de) Präparat zur vorbeugung und behandlung von entzündungen
PL326499A1 (en) Transcutateous therapeutic system (tts) for administration of active substances used in treating narcotic dependence or drug addiction
EP0744176A3 (fr) Médicaments pour inhiber les pertes osseuses
UA50761C2 (uk) Спосіб запобігання та/або лікування серцевих захворювань, фармацевтична композиція та спосіб запобігання та/або лікування серцевої недостатності та дисфункції шлуночків в організмі теплокровної тварини
AU7595298A (en) Azolidinediones useful for the treatment of diabetes, dyslipidemia and hy pertension
AU1948995A (en) Combinations of active insecticide substances
PL330597A1 (en) Transcutaneous systems containing two active ingredients in separate compartments, method of obtaining them and their application as therapeutic agents

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AM AT AU BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GM GW HU IL JP KE KG KP KR KZ LC LK LR LT LU LV MD MG MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TT UA US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AM AT AU BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GM GW HU IL JP KE KG KP KR KZ LC LK LR LT LU LV MD MG MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TT UA US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 1998924097

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2288631

Country of ref document: CA

Ref country code: CA

Ref document number: 2288631

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 09423333

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1998924097

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 1998547652

Format of ref document f/p: F

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 1998924097

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载